LesothoTuberculosis profile
Population  2015 2.1 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.2 (0.63–1.9) 55 (29–89)
Mortality (HIV+TB only) 4.8 (3–7) 223 (139–328)
Incidence  (includes HIV+TB) 17 (11–24) 788 (510–1 125)
Incidence (HIV+TB only) 12 (7.7–18) 566 (359–820)
Incidence (MDR/RR-TB)** 1.1 (0.76–1.5) 52 (36–70)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.54 (0.18–0.9) 5.9 (2.7–9.1) 6.5 (2.9–10)
Males 0.63 (0.36–0.9) 9.7 (6.8–13) 10 (7.2–14)
Total 1.2 (0.72–1.6) 16 (12–19) 17 (11–24)
TB case notifications, 2015  
Total cases notified 7 892
Total new and relapse 7 594
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 96%
          - % pulmonary 86%
          - % bacteriologically confirmed among pulmonary 49%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 45% (32–70)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.37 (0.21–0.61)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 5 258 72%
          - on antiretroviral therapy 4 152 79%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  430
(350–510)
Estimated % of TB cases with MDR/RR-TB 4.8% (3.7–5.9) 14% (9.3–18)  
% notified tested for rifampicin resistance 21% 57% 2 536
MDR/RR-TB cases tested for resistance to second-line drugs   8
Laboratory-confirmed cases MDR/RR-TB: 332, XDR-TB:
Patients started on treatment **** MDR/RR-TB: 217, XDR-TB: 5
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 70% 9 000
Previously treated cases, excluding relapse, registered in 2014 59% 936
HIV-positive TB cases, all types, registered in 2014 69% 5 466
MDR/RR-TB cases started on second-line treatment in 2013 63% 163
XDR-TB cases started on second-line treatment in 2013 33% 3
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions) 6.4
Funding source: 12% domestic, 19% international, 69% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-11 Data: www.who.int/tb/data